Back to journals
Academic Journal

Psychotherapy and Psychosomatics

3 Papers Indexed in Blossom

Published Papers

Open Accessindividual

Long-Term Efficacy of Psilocybin with Adjunct Psychotherapy in Treatment-Resistant Major Depression (EPIsoDE): 6- and 12-Month Naturalistic Follow-Up of a Phase 2b Trial

This naturalistic follow-up of a Phase IIb randomised active placebo-controlled trial (n=144) found that one or two 25 mg doses of psilocybin with psychotherapy were linked to sustained reductions in depression symptoms in treatment-resistant major depression (TRD) at six and twelve months. Benefits were similar across groups, while restarting antidepressant medication during follow-up was associated with worse scores.

Published
Journal
Psychotherapy and Psychosomatics
Authors
Mertens, L. J., Betzler, F., Brand, M., Evens, R., Jungaberle, A., Jungaberle, H., Kärtner, L., Majić, T., Schmitz, C. N., Ströhle, A., Scharf, D., Spangemacher, M., Wolff, M., Assadi, Z., Bahri, S., Becher, L., Färber, L. V., Harder, H., Kirchen, N., Kulakova, E., Kunz, L. C., Meijer, A., Rohrmoser, B., Wellek, S., Berger, M. M., Koslowski, M., Gründer, G.
Paywallindividual

Cognitive Behavioral Therapy to Sustain the Antidepressant Effects of Ketamine in Treatment-Resistant Depression: A Randomized Clinical Trial

In a proof-of-concept randomised sequential trial in treatment‑resistant depression, responders to six ketamine infusions were randomised to 14 weeks of CBT versus treatment‑as‑usual and CBT showed a significant group-by-time advantage on self-report depressive symptoms (QIDS; moderate-to-large Cohen d ≈ 0.71), while the primary clinician-rated outcome (MADRS) showed a non-significant moderate effect (d = 0.65). A subset analysis also found improved accuracy on an emotional N‑back task among ketamine responders.

Published
Journal
Psychotherapy and Psychosomatics
Authors
Wilkinson, S. T., Taeho, G., Rhee, Joormann, J., Webler, R., Ortiz Lopez, M., Kitay, B., Fasula, M., Elder, C., Fenton, L., Sanacora, G.
Paywallindividual

Post-Marketing Safety Concerns with Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System

This study (n=962) investigated adverse events after administration of nasal esketamine (Spravato) for treatment-resistant depression (TRD). The study found increased suicidal ideation (versus antidepressants) but not suicide attempts or completions.

Published
Journal
Psychotherapy and Psychosomatics
Authors
Gastaldon, C., Raschi, E., Kane, J. M., Barbui, C., Schoretsanitis, G.

Quick Facts

Papers Indexed
3
h-Index
123
Open Access
No
Publisher
Karger
Country
Switzerland
Website
Visit